A: Slow weight loss in the first month is completely normal because your doctor is slowly titrating (increasing) your dose to let your body adjust safely
Ohtsu, E., Ichiyama, A., Nishizuka, Y
While these can reduce inflammation, they often bring difficult side effects: Weight gain, bloating, and bone loss Increased infection risk Fatigue and mood changes High long-term costs Because these drugs suppress the immune system instead of balancing it, flare-ups frequently return once treatment stops
Potential Benefits Investigated for gastrointestinal mucosal healing: promoting repair of damaged gut lining in inflammatory bowel conditions, ulcers, and leaky gut Gastric acid stability: uniquely suited for oral delivery among therapeutic peptides because BPC-157 is a native component of gastric juice and resists acid degradation VEGF-mediated angiogenesis: promoting mucosal blood vessel formation essential for tissue repair in chronically inflamed or damaged gut tissue Investigated for inflammatory bowel disease (IBD): preclinical evidence for mucosal protection and anti-inflammatory effects in colitis models Gastroparesis support: pro-motility effects via vagal cholinergic pathways investigated in preclinical models of delayed gastric emptying Leaky gut (intestinal hyperpermeability): tight junction protein support and mucosal integrity restoration investigated in preclinical research Oral route delivers medication directly to the gut mucosa where it is most needed, without requiring injection Convenient capsule administration for daily GI protocols, suitable for patients who cannot or prefer not to self-inject Systemic tissue repair support via potential mucosal absorption at therapeutic doses (extent of systemic absorption is under investigation) May complement injectable BPC-157 protocols for patients with both GI and systemic recovery goals Speak with a physician Interested in BPC-157 (Oral)
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1A, B, and C
